The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels

Cutaneous and Ocular Toxicology

Volumn 33, Issue 4, 2014, Pages 270-274

  Sogutlu Sari, Esin ^a   Yazici, Alper ^a   Eser, Betül ^a   Erol, Muhammet Kazim ^b   Kilic, Adil ^a   Ermis, Sitki Samet ^a   Koytak, Arif ^c   Akşit, Hasan ^a   Yakut, Tahsin ^d  

^a BALIKESIR UNIVERSITY   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^c Antalya EGitim Ve Arastirma Hastanesi Varlik Mahallesi Kazim Karabekir Caddesi SoGuksu   (Turkey)

^d ULUDAG UNIVERSITY   (Turkey)

Author keywords

4G 5G polymorphism of PAI 1 gene; Central serous chorioretinopathy; Serum PAI 1 level

Indexed keywords

GENOMIC DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CENTRAL SEROUS CHORIORETINOPATHY; GENETICS; MIDDLE AGED; PREVALENCE; RISK FACTOR; TURKEY;

ADULT; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; TURKEY;

EID: 84912100853     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2013.854372     Document Type: Article

References (32)

1. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062
2. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121: 26-34
3. Yamada R, Yamada S, Ishii A, Tane S. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 1993;97: 955-966
4. Iijima H, Iida T, Murayama K, et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol 1999;127:477-478
5. Caccavale A, Imparato M, Romanazzi F, et al. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 2009;73: 435-437
6. Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 2001;4:899-903
7. Heaton JH, Dlakic WM, Gelehrter TD. Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost 2003;89: 959-966
8. Liang XN, Xie L, Cheng JW, et al. Association between PAI-1 4G/5G polymorphisms and osteonecrosis of femoral head: a metaanalysis. Thromb Res 2013;132:158-163
9. Zhao L, Bracken MB, Dewan AT, Chen S. Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: a systematic review and meta-analysis. Mol Hum Reprod 2013;19:136-143
10. Kupeli E, Verdi H, Simsek A, et al. Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis. Clin Appl Thromb Hemost 2011;17:87-94
11. Zhang T, Pang C, Li N, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis. BMC Med 2013;11:1
12. Ozkan B, Cagliyan CE, Elbasan Z, et al. PAI-1 4G/5G gene polymorphism is associated with angiographic patency in STelevation myocardial infarction patients treated with thrombolytic therapy. Coron Artery Dis 2012;23:400-403
13. Madách K, Aladzsity I, Szilágyi A, et al. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care 2010;14:R79
14. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855
15. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet 2004;363:157-163
16. Giovannini A, Scassellati-Sforzolini B, D'Altobrando E, et al. Choroidal findings in the course of idiopathic serous pigment detachment detected by indocyanine green videoangiography. Retina 1997;17:286-293
17. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121: 26-34
18. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003;110:698-703
19. Türkcü FM, Yüksel H, Sahin A, et al. Effects of smoking on visual acuity of central serous chorioretinopathy patients. Cutan Ocul Toxicol 2013; Jul 10. [Epub ahead of print
20. Ozdemir O, Erol MK. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab. Cutan Ocul Toxicol 2013; Jul 12. [Epub ahead of print
21. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999;19:508-512
22. Kitaya N, Nagaoka T, Hikichi T. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003;87:709-712
23. Kocabora MS, Durmaz S, Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol 2008;246:1783-1786
24. Singh NK, Gupta A, Behera DR, Dash D. Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome. Rheumatol Int 2013;33:2331-2336
25. Costen MT, Parkin BT, Davison CR, Crick MP. Central serous chorioretinopathy and antiphospholipid antibodies - Results of a pilot study. Eye (Lond) 2004;18:938
26. Grancha S, Estelles A, Torno G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999;81:516-521
27. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-10745
28. Halleux CM, Declerck PJ, Tran SL, et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999;84: 4097-4105
29. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47: 431-448
30. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case control study. Ophthalmology 2004;111:244-249
31. Brozovic M. Physiological mechanisms in coagulation and fibrinolysis. Br Med Bull 1977;33:231-238
32. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010;149:361-363